Embed Size (px)
Citation preview
COMPANY SUMMARY
BIO Boston 1x1 meeting
THERACLION___________
NAME OF THE CEODavid CAUMARTIN
ADDRESS102 Rue Etienne Dolet
92240 Malakoff________________________
www.theraclion.com
MANAGEMENT TEAMCEO: David Caumartin
CFO: David Auregan
CSO or CTO: Sylvain Yon
IRO: David Caumartin / David
Auregan
TARGETEDMARKET
___________Theraclion offers an alternative to
surgery for 1,5 million
fibroadenomas and 1,8 million
thyroids.
Theraclion echotherapy also offers
a potentially non-invasive,
outpatient solution for the treatment
of superficial veins of the lower limb
in a market with global healthcare
costs of ~$9 billion. 5 million
procedures are done every year.
LISTED COMPANY
CREATION DATE2004
MISSION
The r ac l i on d ev e l op s , m anu fac tu r es and m ar k e t s t he Ech o p u lse® m ed i ca l d ev i ce f o r t he non - i nv as i v e , ou tp a t i en t t r ea tm en t o f b r eas t f i b r oad enom as and b en i g n t hy r o i d nod u l es . The r ac l i on i s cu r r en t l y com p l e t i ng t he f i r s t ev e r hum an s tud y on v e i ns w i t h H IFU .
TECHNOLOGY
The r ac l i on i s cu r r en t l y t he on l y com p any i n t he w o r l d o f f e r i ng a com p l e te l y non -i nv as i v e t r ea tm en t f o r b r eas t f i b r oad enom as and b en i g n t hy r o i d nod u l es . I t r e l i es on u l t r as ound - g u i d ed h i g h - i n tens i t y f ocus ed u l t r as ound f o r t he t he r m o- ab l a t i on o f s o f t t i s s ues s uch as t um our s & v e i ns .
COMPETITION- S u r g i ca l ex c i s i on ( D aV i nc i / I n t u i t i v e ) & RFA fo r Thy r o i d ex c i s i on- Ang i od y nam i cs , M ed t r on i cs , f o r V e i ns ( Las e r & RFA)
ALLIANCES/PARTNERSHIPS- Fu r u i M ed i ca l f o r C h i na , E D AP TM S fo r F r ance on B r eas t / Thy r o i d- TBD U S A & V e i ns
UPCOMING CATALYSTS- Geog r ap h i c ex p ans i on f o r cu r r en t i nd i ca t i on t o C h i na and U S A ( 6 t i m es The r ac l i on m ar k e t ) t h r oug h l aunch and com p l e t i on o f r eg u l a to r y c l i n i ca l t r i a l s- C E m ar k i ng on new i nd i ca t i on f o r v e i ns- Onco l og y Res ea r ch con t r ac t s f o r com b i na t i on i m m uno the r ap y /H IFU
MARKET FIGURES
Rev enues 2017 : m€ 2 , 4 D a te o f I P O : 2014T i ck e r : ALTH EE x chang e : E u r onex tGr ow thC ur r ency : E u r oM ar k e t cap : m€ 26P r i ce : € 3 , 552 - w eek s - h i g h : € 5 , 8952 - w eek s - l ow : € 3 , 33Av e r ag e d a i l y v o l um e : 10 K p e r d ay
KEY FIGURES
€ m 2016 2017 Growth (%)Sales 1,8 2,4 +31%EBIT (7,5) (7,1) -5%Net Income (6,5) (6,2) -4%Cash Position 7 4.9 -30%
COMPANY SUMMARY
BIO Boston 1x1 meeting
THERACLION___________
NAME OF THE CEODavid CAUMARTIN
ADDRESS102 Rue Etienne Dolet
92240 Malakoff________________________
www.theraclion.com
MANAGEMENT TEAMCEO: David Caumartin
CFO: David Auregan
CSO or CTO: Sylvain Yon
IRO: David Caumartin / David
Auregan
TARGETEDMARKET
___________Theraclion offers an alternative to
surgery for 1,5 million
fibroadenomas and 1,8 million
thyroids.
Theraclion echotherapy also offers
a potentially non-invasive,
outpatient solution for the treatment
of superficial veins of the lower limb
in a market with global healthcare
costs of ~$9 billion. 5 million
procedures are done every year.
LISTED COMPANY
CREATION DATE2004
ANALYST COVERAGE
Broker Date Reco. (buy/neutral/hol
d)
Target Price Potential (%)
Portzamparc 12/07/2017 Buy € 10,0 +185%InvestSecurities 11/09/2017 Buy € 7,0 +100%
Average: - Buy- € 8,5 +143%
SHAREHOLDERS
PIPELINE
Indications Feasibility Study CE Marking
Breast Fibroadenomas
ü
Benign Thyroid Nodules
ü
Combination immunotherapy/HIF
U
ü
Varicose Veins ü
